Best Peptides for Gut Health

KPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.

BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.

LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.

VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make, first isolated in 1970 by Said and Mutt. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil was tested in humans for COVID-19 respiratory failure, where the largest trial was negative. No VIP product is FDA-approved, including for the wellness, anti-aging, or mold-illness uses it gets marketed for.

Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.

KLOW is a four-peptide blend that adds KPV to the GLOW mix, so it contains GHK-Cu, BPC-157, TB-500, and KPV. It is marketed for healing, anti-inflammatory, and skin and gut benefits, typically sold as a single research vial (commonly around 80 mg total). As with the other blends, none of the peptides is FDA-approved for these uses, and the KLOW combination has never been tested as a product in a clinical trial.

Glepaglutide is Zealand Pharma's long-acting GLP-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. Its path has been bumpy. The FDA rejected it in December 2024 because the single phase 3 trial only worked at the twice-weekly dose, but Europe went the other way: in September 2026 the EMA's CHMP recommended approval under the name Zeydovio. As of late October 2026 the final European Commission decision is still pending, and the US needs another trial.

Apraglutide is a once-weekly GLP-2 analog for short bowel syndrome, originally from VectivBio and now owned by Ironwood Pharmaceuticals. Its phase 3 STARS trial hit its main goal in 2024, but in April 2025 Ironwood said the FDA wanted a confirmatory trial, partly because patients in STARS got less drug exposure than planned due to how doses were prepared and given. That new trial, STARS-2, started in June 2026, so approval is years away (a submission before end of 2029 has been mentioned).

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.